| Migraine Disorders
Ajovy vs Ubrelvy
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Ajovy vs Ubrelvy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUbrelvy has a higher rate of injection site reactions vs Ajovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ubrelvy but not Ajovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ajovy
Ubrelvy
At A Glance
SC injection
Monthly or every 3 months
CGRP antagonist
Oral
As needed
CGRP receptor antagonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 225 mg SC monthly or 675 mg SC quarterly (three consecutive 225 mg injections) into abdomen, thigh, or upper arm.
Episodic migraine Pediatric patients 6 to 17 years weighing 45 kg or more: 225 mg SC monthly.
Migraine Disorders 50 mg or 100 mg orally as needed; a second dose may be taken at least 2 hours after the initial dose; maximum 200 mg per 24-hour period. Dose reductions apply with moderate or weak CYP3A4 inhibitors, BCRP and/or P-gp only inhibitors, and in patients with severe hepatic or severe renal impairment (CLcr 15-29 mL/min); avoid in end-stage renal disease.
Contraindications
- Serious hypersensitivity to fremanezumab-vfrm or any excipient, including anaphylaxis and angioedema
- Concomitant use of strong CYP3A4 inhibitors
- History of serious hypersensitivity to ubrogepant or any component of UBRELVY (reactions have included anaphylaxis, dyspnea, and facial or throat edema)
Adverse Reactions
Most common (>=2%) Injection site reactions (pain, induration, erythema)
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylactic reactions, angioedema, hypertension, Raynaud's phenomenon
Most common (>=2%) Nausea, somnolence, dry mouth
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, pruritus), hypertension, Raynaud's phenomenon
Pharmacology
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby inhibiting CGRP-mediated signaling implicated in migraine.
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; by blocking CGRP receptor signaling it inhibits a pathway implicated in migraine pathophysiology.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ajovy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (7/12) · Qty limit (10/12)
Ubrelvy
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (12/12) · Qty limit (12/12)
UnitedHealthcare
Ajovy
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Ubrelvy
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Ajovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ubrelvy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UbrelvyView full Ubrelvy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.